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A B S T R A C T
Purpose
There are no accurate prognostic biomarkers specific for rectal cancer. Epigenetic aberrations, in
the form of DNA methylation, accumulate early during rectal tumor formation. In a preliminary
study, we investigated absolute quantitative methylation changes associated with tumor progres-
sion of rectal tissue at multiple genomic methylated-in-tumor (MINT) loci sequences. We then
explored in a different clinical patient group whether these epigenetic changes could be correlated
with clinical outcome.
Patients and Methods
Absolute quantitative assessment of methylated alleles was used to assay methylation changes
at MINT 1, 2, 3, 12, 17, 25, and 31 in sets of normal, adenomatous, and malignant tissues from
46 patients with rectal cancer. Methylation levels of these biomarkers were then assessed in
operative specimens of 251 patients who underwent total mesorectal excision (TME) without
neoadjuvant radiotherapy in a multicenter clinical trial.
Results
Methylation at MINT 2, 3, and 31 increased 11-fold (P  .005), 15-fold (P  .001), and two-fold
(P  .02), respectively, during adenomatous transformation in normal rectal epithelium. Unsuper-
vised grouping analyses of quantitative MINT methylation data of TME trial patients demonstrated
two prognostic subclasses. In multivariate analysis of node-negative patients, this subclassifica-
tion was the only predictor for distant recurrence (hazard ratio [HR], 4.17; 95% CI, 1.72 to 10.10;
P  .002), cancer-specific survival (HR, 3.74; 95% CI, 1.4 to 9.43; P  .003), and overall survival
(HR, 2.68; 95% CI, 1.41 to 5.11; P  .005).
Conclusion
Methylation levels of specific MINT loci can be used as prognostic variables in patients with American
Joint Committee on Cancer stage I and II rectal cancer. Quantitative epigenetic classification of rectal
cancer merits evaluation as a stratification factor for adjuvant treatment in early disease.
J Clin Oncol 26:2327-2335. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Rectal cancer is the secondmost common cancer of
the digestive system in the United States.1 Neoadju-
vant therapy has improved local control of rectal
cancer in patients undergoing total mesorectal exci-
sion (TME),2-4 but distant recurrence remains the
major cause of disease mortality. Although tumor
status of regional nodes is the most important pre-
dictor of metastasis, 20% of node-negative patients
will have a recurrence at distant sites. This sug-
gests that even early stages of tumors have poten-
tial for systemic metastasis and, therefore,
molecular subclassification may be clinically rele-
vant. Development of prognostic molecular bi-
omarkers for rectal cancer would improve
management and potential treatment stratifica-
tion. Colon and rectal cancers are often assessed
together in the analysis of molecular/genetic bi-
omarkers. This is often due to the limited avail-
ability of rectal tumor for analysis, or rectal
specimens are not procured from a specific clini-
cal trial. We now know both colon and rectal
cancers are different in etiology and treatment, as
well as (epi)genetics.5 In this study, we have fo-
cused specifically on epigenetic changes of rectal
cancers from a clinical trial.
Epigenetic instability, such as changes in
genomic DNA methylation status, is an early event
during GI tumor development and encompasses
both hyper- and hypomethylation changes.6-8 Most
epigenetic cancer studies focus on specific genomic
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loci and analyze methylation status in a dichotomous manner, cate-
gorizing specimens as methylated or unmethylated. Also, in the ma-
jority of the studies assessing epigenetic changes and association with
clinical outcome, nonquantitative measures are used, using a binary
methylation status result. Absolute quantitative interpretation of
methylation data would improve analysis of epigenetic events.9 Re-
cently, we developed an assay for absolute quantitative assessment of
methylated alleles (AQAMA) and showed quantitative methylation
events to be associated with colorectal tumor progression.10 AQAMA
measures the amountofmethylated andunmethylated copynumbers
simultaneously in a single reaction. The assay has excellent linearity in
assessing DNA methylation levels and can be used on paraffin-
embeddedarchival tissue(PEAT)sections treatedwith theon-slide (in
situ) sodium bisulfite modification (SBM) technique that allows mi-
crodissected histology-oriented assessment of small (1 to 2 mm2)
lesions.11,12 This allows efficient comparison of precursor adenoma
and normal cells adjacent to tumor cells.
Methylation levels of methylated-in-tumor (MINT) loci have
not been specifically tested for prognostic utility in rectal cancer.
MINT loci are CpG dinucleotide–rich regions located in nonprotein-
encoding DNA regions, and have been reported to become methyl-
ated in a tumor- and adenoma-specific manner in gastric and colon
cancer.13-17 In apreliminary study,wequantifiedmethylation levels of
sevenMINT loci atdifferent stagesof rectal tumor formationcompar-
ing paired normal-adenoma and adenoma-cancer tissues, and subse-
quently analyzed whether methylation level changes related to rectal
tumor progression. Our developed hypothesis was that methylation
levels atMINT loci have prognostic significance for early rectal cancer
progression. We then assessed the potential prognostic utility of
MINT loci in primary tumor tissues from patients enrolled in a mul-
ticenter, randomized, surgical clinical trial. In this translational study
analysis, unsupervised cluster analysis identified a subclass of patients
whose quantitative methylation data were independently prognostic
of progression to distant disease.
PATIENTS AND METHODS
Tissue Specimens
In the preliminary study, patients who underwent surgery for rectal
cancerwith histopathologic-confirmed adenocarcinomawere identified from
the cancer registry database at Saint John’sHealthCenter (SantaMonica,CA).
Only patients who underwent surgery after 1995 were evaluated because of
possible DNA degradation. Further selection of specimens was based on
pathology-documented presence of tumor, as well as adenoma cells on the
same tissue section.
For theclinical correlationstudies,primary tumorPEATspecimenswere
obtained from 322 nonirradiated patients enrolled onto themulticenter, ran-
domized, quality-controlled TME trial coordinated by the Dutch Colorectal
Cancer Group.3 The trial investigated whether neoadjuvant radiotherapy
(5  5 Gy) before TME improved local control compared with TME
surgery alone in patients with all stages of rectal cancer. Trial eligibility
criteria and follow-up protocols have been described previously.3,18,19 All
TME trial patients enrolled at the Dutch multicenter study sites were eligible,
further adhering to the following criteria: nonirradiated,TNMstage I-III,with
no evidence of disease after surgery. We opted to analyze the nontreatment
arm because potential effects of radiation on genomic methylation are not
known. Research protocols for the methylation studies on PEAT were ap-
proved by the internal review boards of Saint John’s Health Center, John
Wayne Cancer Institute (Santa Monica, CA), and Leiden University Medi-
cal Center (Leiden, the Netherlands).
DNA Preparation From PEAT Specimens for Preliminary and
Clinical Studies
From the preliminary study specimens, two consecutive sections (4 and
7m)of each PEATblockwere cut and placed on adhesive-coated slides. The
4 m section was stained with hematoxylin and eosin (H&E) and mounted.
Tissue areas with normal epithelial, classic adenomatous, and invasive cancer
cells were identified and marked by an expert surgical pathologist (R.R.T.).
The tissue categories were identified by histopathology. Cancer cells were only
taken from areas with nuclear atypia and signs of invasion of tissue architec-
tural boundaries, the hallmark of cancer. Adenomatous cells were only taken
from areas with classic villous and/or tubular adenomatous dysplasia.We did
not include adenomatous tissue in the analysis with highly dysplastic features
without signs of invasion. The 7-m section was treated by on-slide SBM as
described previously.11 Target tissue areas were identified andmicrodissected
under a lightmicroscope. Isolated cellsweredigestedand1Lof the lysatewas
used for polymerase chain reaction.
From the clinical study of TME trial patient specimens, tissue sections (7
m) were cut from PEAT specimens and mounted on nonadhesive glass
slides. Tumor-representative areas onH&E-stained sectionsweremarkedby a
surgical pathologist specializing in rectal cancer (J.H.J.M.vK.). Two sections
per patientwere deparaffinized, and themarked tissuewas carefullymicrodis-
sected. DNA was isolated and modified by sodium bisulfite, as previously
described.20 Salmon sperm DNA was added as a carrier.21 Double-stranded
DNA and single-stranded DNA were quantified before and after SBM by
PicoGreenandOliGreenassays (MolecularProbes; Invitrogen,Carlsbad,CA),
respectively. Sufficient input DNA for AQAMA was determined as de-
scribed.10 A salmon spermDNA samplewithout tumorDNAwas included in
triplicate to assess background signal in all assays. Tissue blocks and isolated
DNAwere coded to prevent any bias.
AQAMA MINT Locus Methylation Level Assessment
Absolute quantitative assessment ofmethylated alleles atMINT loci 1, 2,
12, and 31 has been described previously.10 Unpublished primer and probe
sets for the remaining three MINT loci were: MINT3, 5-TGATGGTGTAT
GTGATTTTGTGTT-3(forward),5-ACCCCACCCCTCACAAAC-3(reverse),
5-ACCTACGAACGAACAC-3(methylated probe), 5-TACCTACAAAC
AAACAC-3(unmethylated probe); MINT17, 5-AGGGGTTAGGTTG
AGGTTGTT-3(forward),5-TCTACCTCTTCCCAAATTCCA-3(reverse),5-
TTGGATGGATCGCGG-3 (methylated probe), 5-TATTTTGGATGGA
TTGTGG-3(unmethylated probe); and MINT25, 5-GGGGATAGGAAGA
TGGTTT-3(forward), 5-CCCCCATCCCATACAACC-3(reverse), 5-TTT
GTTTCGTAGCGGAGT-3(methylated probe), 5-GATTTTGTTTTGTAGT
GGAG-3 (unmethylatedprobe).DNAsampleswere run in384-wellmicroplates
in triplicate, and each plate contained individualmarker cDNA standards with
known copy numbers, allowing assessment of absolute methylated and
unmethylated copy number. Controls for specificity of AQAMA for meth-
ylated and unmethylated sequences, as well as controls for nonspecific ampli-
fication,were included.10,22 Final analysis outcomewas themethylation index
(MI), calculated as: [copy numbermethylated alleles/(copy numbermethylated alleles
 copy numberunmethylated alleles)].
Profiling by Unsupervised Random Forest Clustering
For identification of patient clusters with similar MINT locus methyl-
ationprofiles, we employedunsupervised random forest (RF) clustering.23 RF
has been successfully applied in comparable data sets (Appendix 1, on-
line only).24,25
RESULTS
MINT Locus Methylation Levels During Rectal
Cancer Development
Sets of normal, adenomatous, andmalignant PEAT tissues from
46 patients with rectal cancer were examined by AQAMA of MINT
loci known to be differentially methylated in colorectal cancer.12 The
H&E-stained sections cut from the tissue blocks that, according to the
de Maat et al
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Fig 1. Scatterplots of measured methylation indices in normal rectal epithelium, rectal adenoma tissue, and rectal cancer tissue for the 7 MINT loci studied. MINT,
methylated in tumor; ns, not significant.
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diagnostic pathology report, contained adenoma as well as cancer
tissue, were evaluated histopathologically by an expert pathologist
(R.R.T). In the 46 tissue sections, 19, 46, and 35 areas of normal
epithelium, adenoma, and cancer tissue, respectively, were identified.
This resulted into paired analyses of 19 normal-adenoma sets and 35
adenoma-cancer sets. Figure 1 shows scatterplots of the MI values in
the threehistopathologycategories for eachMINTlocus.MINTloci 2,
3, and 31 underwent a significant increase in absolute mean methyl-
ation level duringadenomatous transformation.Therewereno signif-
icant MINT methylation changes for any MINT locus during
progression from adenoma to cancer. Subsequently, the significant
increases were early events associated with dysplastic change of nor-
mal rectal epithelium. Because threeMINT loci (2, 3, and 31) showed
significant increase in methylation levels and the normal distribution
of the quantitative methylation data sets in healthy rectal epithelium
changes to non-normal in adenoma in four other loci (1, 12, 17, and
25; Appendix 2 and Table A1, online only), all sevenMINT loci were
considered to have potential utility to identify epigenetic subclasses in
the clinical study patient group.
Sample Size Calculations
To establish the sample size for the clinical study, we performed
power calculations usingmethylation results of the preliminary study
and recurrence rates of the TME trial. It was calculated that 250
patients were sufficient to obtain significance for predicting distant
recurrence with an  level of .05% and 90% power. Because the
available patient specimens from the trial were primary tumor PEAT
blocks from various hospital sites, we allowed for 30% loss of patient
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Fig 2. Methylated in tumor (MINT) locus methylation subclass identification. (A) multidimensional scaling [MDS] plot displaying the level of dissimilarity between all
patients (MDS plot axes represent arbitrary units, and are therefore dimensionless). (B) Three-dimensional plot representing expectation maximization algorithm with
a mixture of Gaussians analysis of the MDS plot coordinates showing Gaussian distribution (bell-shaped) of the two identified clusters. (C) MDS plot showing final
cluster allocations for the patient population. (D) Box plots comparing the differences in methylation levels (MI) between cluster 1 and 2 for all MINT loci.
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samples due to availability and quality of tissue and DNA. We there-
fore required 75 additional patient samples, and the final sample size
was set at 325 patients samples. Six hundred seventy-two patients
fulfilled our study criteria (see Patients and Methods). Finally, DNA
was isolated in 314 patient samples (in 11 patient samples, tumor cell
number was insufficient). Subsequently, after processing and bisulfite
treatment, only 251 of the 314DNA isolations had sufficient inputDNA
forAQAMA.Characteristics of the 251 patients in the final analysis were
not significantly different in prognostic factors and characteristics from
the original trial population (AppendixTableA2, online only).
Table 1. Variable Importance by Gini Index and Comparison of Mean MINT Locus Methylation Index Values Between Identified Clusters
MINT
Locus
Gini
Index
All Patients (n  251) Node-Negative Patients (n  145)
Cluster 1 (n  89) Cluster 2 (n  162)
P 
Cluster 1 (n  55) Cluster 2 (n  90)
P Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range Median
Interquartile
Range
MINT1 11.6 0.00 0.00-0.01 0.01 0.00-0.09  .001 0.00 0.00-0.02 0.00 0.00-0.09 .006
MINT2 10.8 0.08 0.00-0.02 0.00 0.00-0.12 .07 0.00 0.00-0.03 0.00 0.00-0.10 .51
MINT3 20.2 0.87 0.79-0.99 0.50 0.06-0.65  .001 0.84 0.79-0.99 0.49 0.06-0.65  .001
MINT12 13.5 0.03 0.00-0.02 0.02 0.01-0.05 .01 0.02 0.00-0.02 0.02 0.00-0.05 .22
MINT17 20.7 0.08 0.04-0.13 0.21 0.08-0.30  .001 0.09 0.05-0.15 0.20 0.12-0.24 .005
MINT25 12.1 0.00 0.00-0.04 0.00 0.00-0.08 .21 0.00 0.00-0.05 0.00 0.00-0.09 .81
MINT31 6.0 0.00 0.00-0.00 0.00 0.00-0.00 .90 0.00 0.00-0.00 0.00 0.00-0.00 .82
Abbreviation: MINT, methylated in tumor.
Calculated by Mann-Whitney’s U test.
Table 2. Comparison of Clinical and Tumor Pathology Factors and MINT Locus Clusters
Clinical and Tumor Pathology
Factors
All Patients (n  251)
P
Node-Negative Patients (145)
P
Cluster 1
(n  89)
Cluster 2
(n  162)
Cluster 1
(n  55)
Cluster 2
(n  90)
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Sex
Male 64 39 98 61 .08 38 40 56 60 .40
Female 25 28 64 72 17 33 34 67
Age, years
Mean 64.8 62.5 .15 65.4 63.4 .33
SE 1.2 0.9 1.7 1.2
TNM stage
I 29 41 41 59 .22 29 41 41 59 .40
II 26 35 49 65 26 35 49 65
III 34 32 72 68 — —
N status
N0 ( 12 examined) 12 35 22 65 .53 12 35 22 65 .84
N0/NX ( 12 examined) 44 39 68 61 43 39 68 61
N1 (1-3 positive) 21 34 40 66 — —
N2 ( 4 positive) 12 27 32 73 — —
Differentiation
Well 5 28 13 72 .78 3 33 6 67 .99
Moderately 66 37 110 63 44 39 70 61
Poor 18 32 39 68 8 36 14 64
Location of distant recurrences
Liver 11 41 16 59 .62 4 50 4 50 .37
Not liver 20 49 21 51 11 73 4 27
Resection type
Low anterior 54 32 113 68 .26 32 34 62 66 .35
Abdominoperineal 33 43 44 57 21 47 24 53
Hartmann 2 29 5 71 2 33 4 67
Circumferential margin
Negative 72 35 131 65 .39 52 39 81 61 .54
Positive 17 35 31 65 3 25 9 75
Abbreviation: MINT, methylated in tumor.
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MINT Locus Methylation Profile Identification
To investigate whether rectal cancer can be grouped by methyl-
ation level at specific MINT loci, we performed unsupervised RF
clustering on the quantitative methylation level results of patients
from the TME trial. As an outcome, a multidimensional scaling
(MDS) plot indicated themutual distance between the samples based
onmethylation level of all sevenMINT loci (Fig 2A). Inspectionof the
MDS plot indicated two groups of rectal cancer cases. To identify
which patients belonged to which group, we performed an expecta-
tionmaximizationalgorithmwith amixtureofGaussians (EM-MoG)
analysis based on the Gaussian shape of patient clusters (Figs 2B and
2C). The EM-MoG algorithm allocated the patients based on the
likelihood that they would fall under the normal (Gaussian) distribu-
tion of one of the two clusters. Subsequently, variable importance and
the methylation patterns matching the identified clusters were ana-
lyzed (Fig 2D; Table 1). The 89 patients (35%) allocated to cluster
1 had significantly increased methylation at MINT3 and signifi-
cantly decreasedmethylation atMINT1, 12, and 17 comparedwith
patients in cluster 2. The unsupervised clustering results showed
that subclasses of rectal cancers could be identified by differences in
DNA methylation level of tested MINT loci. The Gini index indi-
cated thatMINT3 andMINT17 were themost important variables
in forming the clusters.
Clinicopathologic Correlation and Distant
Recurrence Analyses
There were no significant associations observed in epigenetic
subclasses of rectal cancer to any of the investigated standard clinical
or tumor-pathological factors (Table 2). Thepreliminary results dem-
onstrated that methylation level differences at the specific MINT loci
develop early during tumor formation. There was no significant rela-
tion between cluster allocation and clinicopathologic factors in node-
negative tumors (Table 2). Because identification of stage I and II
patients at risk for distant metastasis is clinically highly relevant and
there was no dependence of the identified patient clusters to nodal
status, we excluded stage III patients from distant disease recurrence
analyses. We assessed the probability of distant disease recurrence,
cancer-specific, and overall survival (OS). Because EM-MoG analysis
is a probability-based cluster assignment algorithm, we performed
multiple imputation analysis to correct for cases that have a small
difference in probability to be assigned to either one of the clusters. In
node-negative patients, cluster 1 patients had significant increased
risk for distant recurrence (P .01), shorter cancer-specific survival
(P  .02), and shorter OS (P  .05; Figs 3A to 3C). At the time of
the analyses, median duration of follow-up was 7.1 years (range, 2.5
to 9.8 years).
Multivariate Analyses
Multivariate analyses were performed to assess whether the ob-
servedprognostic valueof the clusterswas independent fromstandard
prognostic variables for the complete patient group and for node-
positive and negative patients (Table 3). T stage, N stage, circumfer-
ential margin status, distance of the tumor to the anal verge, and
tumor differentiationwere considered in aCox regression analysis. In
node-negative patients, the quantitative MINT locus methylation
profile—of all the consideredvariables—was theonly selectedpredic-
tive factor for distant disease recurrence and cancer-specific survival.
OSwasalsoaffectedbyT-stage inpatientswithoutnodal involvement.
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Fig 3. (A) Kaplan-Meier plots grouping analyzed node-negative total meso-
rectal excision trial patients into clusters 1 and 2 and comparing postoperative
distant recurrence free survival probability. (B) Cancer-specific and (C) overall
survival are plotted.
de Maat et al
2332 © 2008 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
from 131.174.248.56
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on November 12, 2012
Copyright © 2008 American Society of Clinical Oncology. All rights reserved.
Circumferentialmargin involvementof the tumorandshort (5cm)
distance of the tumor from the anal verge increased the risk of distant
recurrence, and decreased cancer-specific survival and OS in node-
positive rectal cancer patients. Possible dependence of the results on
any of the 42 different study sites was evaluated in the published
clinical trial report26 and was also ruled out (data not shown) in our
analyses. The multivariate results show that the identified subclass of
rectal cancers is independently predictive of distant recurrence in
node-negative patients.
MINT3 and MINT17
The Gini index, indicating variable importance in RF clustering
as shown in Table 1, demonstratedMINT3 andMINT17 to hold the
most information to form the two clusters compared with the other
fiveMINT loci.We continued to assess whether methylation levels at
MINT3 andMINT17 have prognostic value as a separate marker set.
The quantitative methylation data of MINT3 and MINT17 were en-
tered into the RF algorithm and the resulting MDS plot is shown in
Figure 4A. Four clearly separate clusters are formed and the corre-
sponding methylation level differences between the clusters are plot-
ted in Figure 4B.Cluster 3, with 67 patients (27%), corresponds to the
previously identified high-risk cluster 1 because the average MINT3
methylation index is relatively high and the MINT17 methylation
index is relatively low. In Kaplan-Meier analysis, cluster 3 patients are
shown to be at significantly increased risk for distant metastasis in
node-negative patients compared with the other three clusters (Fig
4C). In multivariate analysis, the results showed that the high-risk
cluster 3 was selected as the only independent factor among the
variables analyzed that in node-negative patients predicted distant
recurrence probability (hazard ratio [HR], 2.84; 95% CI, 1.22 to
6.62; P .02), cancer-specific survival (HR, 3.29; 95% CI, 1.33 to
8.12;P .01), andOS(HR,2.21; 95%CI, 1.13 to4.29;P .02). Itwas
concluded that patients at increased risk for distant metastasis can be
defined as having tumors with aMINT3methylation level more than
0.72 and MINT17 methylation level less than 0.14. The analysis also
demonstrated that the specific combination of increasedmethylation
at MINT3 and decreased methylation at MINT17 is required for the
prognostic information.
DISCUSSION
Most studies of biomarkers in large bowel adenocarcinoma include
both the colon and the rectum, even though rectal and colon cancers
are treated differently. Moreover, right-sided and left-sided bowel
adenocarcinomashave differentmolecular patterns;microsatellite in-
stability and methylator phenotype are rarely seen in the rectum.27
Our data represent one of the largest clinical analyses of methylation
biomarkers in rectal cancer specifically, and to our knowledge also
demonstrate the first quantitative correlation betweenMINTmethyl-
ation levels and disease progression.
The preliminary study demonstrated a progressive increase in
methylation levels of specific MINT loci comparing normal and ad-
enomatous rectal tissue. No significant change inmethylation level at
any MINT locus was detected comparing adenomatous and malig-
nant rectal tissue. A correlation between methylation of MINT loci
and development of adenomatous dysplasia has been reported.17 Our
data are unique, as we used paired normal-adenoma cancer speci-
mens, quantitative techniques, and analyzed rectal cancers only. The
results of our clinical study identified two prognostic categories of
Table 3. Multivariate Analysis Results of All Patients and Node-Negative Patients
Variable
All Patients
(n  251)
Node Negative
(n  145)
Node Positive
(n  106)
HR 95% CI P HR 95% CI P HR 95% CI P
Distant recurrence
T stage (3/4) 1.70 0.92 to 3.16 .09 1.19 0.49 to 2.93 .70 2.91 1.01 to 8.37 .05
Nodal status () 2.47 1.44 to 4.23 .001 — — — NS
Circumferential margin () 1.87 1.07 to 3.28 .03 2.40 0.62 to 9.39 .21 1.77 0.94 to 3.33 .08
Distance from anal verge  5 cm 0.71 0.43 to 1.18 .19 1.50 0.59 to 3.85 .40 0.50 0.27 to 0.92 .03
Poor differentiation 1.39 0.81 to 2.38 .23 1.24 0.40 to 3.89 .71 1.59 0.84 to 3.01 .16
MINT locus profile (cluster 1) 1.68 1.03 to 2.73 .04 4.17 1.72 to 10.10 .002 1.11 0.59 to 2.09 .75
Cancer-specific survival
T-stage (3/4) 2.12 1.07 to 4.19 .03 1.88 0.70 to 5.04 .21 2.85 0.98 to 8.26 .05
Nodal status () 2.47 1.41 to 4.35 .002 — — — NS
Circumferential margin () 1.93 1.09 to 3.41 .02 2.28 0.59 to 8.81 .23 1.88 0.99 to 3.56 .05
Distance from anal verge  5 cm 0.59 0.35 to 0.99 .05 1.46 0.53 to 4.03 .46 0.40 0.22 to 0.75 .004
Poor differentiation 1.56 0.91 to 2.70 .11 1.28 0.41 to 4.06 .67 1.70 0.88 to 3.29 .12
MINT locus profile (cluster 1) 1.47 0.88 to 2.45 .15 3.74 1.48 to 9.43 .005 0.99 0.51 to 1.93 .98
Overall survival
T stage (3/4) 1.92 1.14 to 3.23 .01 2.12 1.05 to 4.29 .04 1.98 0.87 to 4.50 .10
Nodal status () 1.88 1.22 to 2.92 .004 — NS — NS
Circumferential margin () 1.66 1.02 to 2.69 .04 1.65 0.60 to 4.53 .33 1.66 0.95 to 2.91 .08
Distance from anal verge  5 cm 0.69 0.45 to 1.06 .09 0.96 0.49 to 1.90 .92 0.55 0.32 to 0.95 .03
Poor differentiation 1.33 0.84 to 2.09 .22 1.06 0.45 to 2.47 .90 1.37 0.77 to 2.44 .28
MINT locus profile (cluster 1) 1.48 0.98 to 2.24 .06 2.68 1.41 to 5.11 .003 1.00 0.57 to 1.77 1.00
Abbreviations: HR, hazard ratio; MINT, methylated in tumor; NS, not significant.
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rectal cancer based strictly on the absolute quantitative differences in
methylation level. Our data show that methylation levels at multiple
and two specific identified MINT loci are related to rectal tumor
formation, and that they may be seen as surrogate markers of distant
rectal cancer disease recurrence and disease survival. The role of non-
codingregionshasbeenofmuch interest in that itmaybe influential in
gene encoding regions.28-30 Especially interesting is that the chromo-
somal location (1p36) of theMINT3 locus, which undergoesmethyl-
ation in most rectal adenomas, contains many cancer-related genes.
MethylationofMINTloci 1, 2, 12, and31 isoften studied in relation to
theCpGislandmethylatorphenotype (CIMP) that formsa subclass of
right colon tumors closely associated with microsatellite instability.31
In our study, the unsupervised clustering analyses did not identify a
CIMP associated with hypermethylation in the selected MINT loci
(data not shown). Interestingly, a combination of relative hyper- as
well as hypomethylation was observed in the identified subclasses.
This specific combinationwas even required to showprognostic value
on rectal cancer distant recurrence rates. This corroborates thatCIMP
does not occur in the rectumand that rectal cancermayhave different
epigenetic pathologic changes compared with proximal colon adeno-
carcinoma. Reported correlations betweenMINT 1, 2, 12, and 31 and
clinicopathologic features overlap with the features of microsatellite
instability (positive) tumors (right-sidedness, poor differentiation,
early stage) and therefore our results cannot be compared.27,32,33 We
previously showed relevance of the AQAMA technique testingmeth-
ylation levels at MINT 1, 2, 12, and 31 and increased methylation at
this loci detected by the AQAMA assay was significantly correlated to
right-sided colon tumors.10
Our preliminary study data indicate that methylation events at
themeasuredMINT loci are related to early dysplastic proliferation of
subclasses of rectal premalignancies, andMINT loci may be a clinical
biomarker. Subsequently, in a large rectal cancer patient group, RF
clustering was able to identify—in an unbiasedmanner—two groups
of rectal cancer patients that were naturally present within the quan-
titative methylation data. This demonstrated that subclassification of
rectal cancer patients can be made based on absolute quantitative
methylation level differences.
TherewasnocorrelationbetweenMINTmethylationprofileand
nodal status; in node-negative patients, theMINTprofilewas the only
selected variable in multivariate analyses for distant recurrence prob-
ability and, subsequently, for cancer-specific survival. Identifying
stage I and II patients at risk for distant disease recurrence and assess-
ing primary tumors for predictive genomic biomarkers would be
important for stratifying adjuvant treatment. Moreover, given that
accurate upstaging from stage II to III remains a difficult task,34 we
approached this by a quantitative analysis of a specific panel of epige-
netic biomarkers. The advantage of using genomic analysis is the
stability of DNA comparedwithmRNA in PEAT, where, in the latter,
there is a higher level of degradationwith time. Additional studies will
involve validation in a prospective clinical trial.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
The author(s) indicated no potential conflicts of interest.
AUTHOR CONTRIBUTIONS
Conception and design:Michiel F.G. de Maat, Cornelis J.H. van de
Velde, Martijn P.J. van der Werff, Naoyuki Umetani, Elma Meershoek
A
B
C
0
P = .03
n = 145
Di
st
an
t R
ec
ur
re
nc
e 
Fr
ee
Su
rv
iv
al
 P
ro
ba
bi
lit
y
Time (years)
1.0
0.8
0.6
0.4
0.2
2 4 6 8 10
Cluster 1, 2 and 4 (n = 108)
Cluster 3 (n = 37)
Cluster 1
Cluster 2
Cluster 3
Cluster 4
1 2 3 4
0
0.5
1.0
0
0.5
1.0
M
I V
al
ue
 M
IN
T1
Cluster
1 2 3 4
0
0.2
0.4
0.6
0.8
M
I V
al
ue
 M
IN
T2
Cluster
1 2 3 4
M
I V
al
ue
 M
IN
T3
Cluster
1 2 3 4M
I V
al
ue
 M
IN
T1
2
Cluster
1 2 3 4M
I V
al
ue
 M
IN
T1
7
Cluster
1 2 3 4M
I V
al
ue
 M
IN
T2
5
Cluster
1 2 3 4M
I V
al
ue
 M
IN
T3
1
Cluster
0
0.5
1.0
0
0.5
1.0
0
0.5
1.0
0
0.5
1.0
Fig 4. Random forest analyses using only MINT3 and 17 quantitative methyl-
ation data as input. (A) Multidimensional scaling plot showing the four clusters.
(B) Box plots comparing the differences in methylation levels (MI) between the
four clusters. (C) Kaplan-Meier plot illustrates the distant recurrence probability
between high-risk cluster 3 and the combined clusters 1, 2, and 4.
de Maat et al
2334 © 2008 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
from 131.174.248.56
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on November 12, 2012
Copyright © 2008 American Society of Clinical Oncology. All rights reserved.
Klein-Kranenbarg, J. Han J.M. van Krieken, Rob A.E.M. Tollenaar,
Dave S.B. Hoon
Financial support: Cornelis J.H. van de Velde, Dave S.B. Hoon
Administrative support: Cornelis J.H. van de Velde, Dave S.B. Hoon
Provision of study materials or patients: Cornelis J.H. van de Velde,
Roderick R. Turner, Anton Bilchik
Collection and assembly of data:Michiel F.G. de Maat,
Roderick R. Turner
Data analysis and interpretation:Michiel F.G. de Maat, Cornelis J.H.
van de Velde, Martijn P.J. van der Werff, Hein Putter, Naoyuki Umetani,
Elma Meershoek Klein-Kranenbarg, J. Han J.M. van Krieken,
Rob A.E.M. Tollenaar
Manuscript writing:Michiel F.G. de Maat, Cornelis J.H. van de Velde,
Martijn P.J. van der Werff, Hein Putter, Naoyuki Umetani, Elma
Meershoek Klein-Kranenbarg, Roderick R. Turner, J. Han J.M. van
Krieken, Rob A.E.M. Tollenaar, Dave S.B. Hoon
Final approval of manuscript:Michiel F.G. de Maat, Cornelis J.H. van
de Velde, Martijn P.J. van der Werff, Hein Putter, Naoyuki Umetani,
Elma Meershoek Klein-Kranenbarg, Roderick R. Turner, J. Han J.M. van
Krieken, Rob A.E.M. Tollenaar, Dave S.B. Hoon
REFERENCES
1. Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Improved survival with preoperative radio-
therapy in resectable rectal cancer: Swedish Rectal
Cancer Trial. N Engl J Med 336:980-987, 1997
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al:
Preoperative radiotherapy combined with total me-
sorectal excision for resectable rectal cancer. N Engl
J Med 345:638-646, 2001
4. Bosset JF, Collette L, Calais G, et al: Chemo-
therapy with preoperative radiotherapy in rectal can-
cer. N Engl J Med 355:1114-1123, 2006
5. Iacopetta B: Are there two sides to colorectal
cancer? Int J Cancer 101:403-408, 2002
6. Jones PA, Gonzalgo ML: Altered DNA methyl-
ation and genome instability: A new pathway to can-
cer? Proc Natl Acad Sci U S A 94:2103-2105, 1997
7. Jones PA, Baylin SB: The fundamental role of
epigenetic events in cancer. Nat Rev Genet 3:415-
428, 2002
8. Baylin SB, Herman JG: DNA hypermethyl-
ation in tumorigenesis: Epigenetics joins genetics.
Trends Genet 16:168-174, 2000
9. Zeschnigk M, Bohringer S, Price EA, et al: A
novel real-time PCR assay for quantitative analysis
of methylated alleles (QAMA): Analysis of the reti-
noblastoma locus. Nucleic Acids Res 32:e125, 2004
10. de Maat MF, Umetani N, Sunami E, et al:
Assessment of methylation events during colorectal
tumor progression by absolute quantitative analysis of
methylated alleles. Mol Cancer Res 5:461-471, 2007
11. Umetani N, de Maat MF, Sunami E, et al:
Methylation of p16 and Ras association domain
family protein 1a during colorectal malignant trans-
formation. Mol Cancer Res 4:303-309, 2006
12. Toyota M, Ho C, Ahuja N, et al: Identification
of differentially methylated sequences in colorectal
cancer by methylated CpG island amplification. Can-
cer Res 59:2307-2312, 1999
13. Issa JP, Shen L, Toyota M: CIMP, at last.
Gastroenterology 129:1121-1124, 2005
14. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG
island methylator phenotype in colorectal cancer.
Proc Natl Acad Sci U S A 96:8681-8686, 1999
15. Toyota M, Ohe-Toyota M, Ahuja N, et al:
Distinct genetic profiles in colorectal tumors with or
without the CpG island methylator phenotype. Proc
Natl Acad Sci U S A 97:710-715, 2000
16. Toyota M, Ahuja N, Suzuki H, et al: Aberrant
methylation in gastric cancer associated with the
CpG island methylator phenotype. Cancer Res 59:
5438-5442, 1999
17. Wynter CV, Kambara T, Walsh MD, et al: DNA
methylation patterns in adenomas from FAP, multi-
ple adenoma and sporadic colorectal carcinoma pa-
tients. Int J Cancer 118:907-915, 2006
18. Peeters KC, Kapiteijn E, van de Velde CJ:
Managing rectal cancer: The Dutch experience.
Colorectal Dis 5:423-426, 2003
19. Kapiteijn E, van de Velde CJ: Developments
and quality assurance in rectal cancer surgery. Eur J
Cancer 38:919-936, 2002
20. Spugnardi M, Tommasi S, Dammann R, et al:
Epigenetic inactivation of RAS association domain
family protein 1 (RASSF1A) in malignant cutaneous
melanoma. Cancer Res 63:1639-1643, 2003
21. Herman JG, Graff JR, Myohanen S, et al:
Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad
Sci U S A 93:9821-9826, 1996
22. Umetani N, de Maat MF, Mori T, et al: Syn-
thesis of universal unmethylated control DNA by
nested whole genome amplification with phi29 DNA
polymerase. Biochem Biophys Res Commun 329:
219-223, 2005
23. Liaw A, Wiener M: Classification and regres-
sion by random forest. R News 2/3:18-22, 2002
24. Seligson DB, Horvath S, Shi T, et al: Global
histone modification patterns predict risk of prostate
cancer recurrence. Nature 435:1262-1266, 2005
25. Shi T, Seligson D, Belldegrun AS, et al: Tumor
classification by tissue microarray profiling: Random
forest clustering applied to renal cell carcinoma.
Mod Pathol 18:547-557, 2005
26. Kapiteijn E, Kranenbarg EK, Steup WH, et al:
Total mesorectal excision (TME) with or without
preoperative radiotherapy in the treatment of pri-
mary rectal cancer: Prospective randomised trial
with standard operative and histopathological tech-
niques—Dutch ColoRectal Cancer Group. Eur J Surg
165:410-420, 1999
27. van Rijnsoever M, Grieu F, Elsaleh H, et al:
Characterisation of colorectal cancers showing hy-
permethylation at multiple CpG islands. Gut 51:797-
802, 2002
28. Willingham AT, Gingeras TR: TUF love for
“junk” DNA. Cell 125:1215-1220, 2006
29. Wang J, Gonzalez KD, Scaringe WA, et al:
Evidence for mutation showers. Proc Natl Acad Sci
U S A 104:8403-8408, 2007
30. Lin SL, Ying SY: Gene silencing in vitro and in
vivo using intronic microRNAs. Methods Mol Biol
342:295-312, 2006
31. Weisenberger DJ, Siegmund KD, Campan M,
et al: CpG island methylator phenotype underlies
sporadic microsatellite instability and is tightly asso-
ciated with BRAF mutation in colorectal cancer. Nat
Genet 38:787-793, 2006
32. Ward RL, Cheong K, Ku SL, et al: Adverse
prognostic effect of methylation in colorectal cancer
is reversed by microsatellite instability. J Clin Oncol
21:3729-3736, 2003
33. Hawkins N, Norrie M, Cheong K, et al: CpG
island methylation in sporadic colorectal cancers and
its relationship to microsatellite instability. Gastroen-
terology 122:1376-1387, 2002
34. Bilchik AJ, Nora DT, Sobin LH, et al: Effect of
lymphatic mapping on the new tumor-node-
metastasis classification for colorectal cancer. J Clin
Oncol 21:668-672, 2003
■ ■ ■
Appendix
The Appendix is included in the full-text version of this article, available online at www.jco.org. It is not included in the PDF version
(via Adobe® Reader®).
Absolute Quantitative Methylation in Rectal Cancer
www.jco.org © 2008 by American Society of Clinical Oncology 2335
from 131.174.248.56
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITEITSBIBLIOTHEEK on November 12, 2012
Copyright © 2008 American Society of Clinical Oncology. All rights reserved.
